The Fort Worth Press - In abortion pill case, US high court may undermine drug regulator

USD -
AED 3.672499
AFN 64.491398
ALL 81.720038
AMD 360.406323
ANG 1.790403
AOA 917.999867
ARS 1568.130552
AUD 1.509003
AWG 1.8025
AZN 1.699464
BAM 1.781807
BBD 2.01075
BDT 124.174373
BGN 1.77347
BHD 0.376714
BIF 3006.969435
BMD 1
BND 1.287933
BOB 11.65581
BRL 5.949501
BSD 0.998315
BTN 92.467544
BWP 14.234045
BYN 2.99713
BYR 19600
BZD 2.007835
CAD 1.43395
CDF 2280.000162
CHF 0.840443
CLF 0.025921
CLP 1017.646791
CNY 6.67775
CNH 6.675365
COP 3427.686421
CRC 446.863754
CUC 1
CUP 23.960279
CVE 100.455519
CZK 22.29975
DJF 177.779802
DKK 6.814905
DOP 60.22867
DZD 136.148135
EGP 53.415023
ERN 15
ETB 163.858971
EUR 0.91135
FJD 2.29155
FKP 0.764421
GBP 0.764526
GEL 2.593319
GGP 0.764421
GHS 11.755113
GIP 0.764421
GMD 74.000048
GNF 8850.726552
GTQ 7.630848
GYD 208.864392
HKD 7.83895
HNL 26.834601
HRK 6.831965
HTG 130.916048
HUF 340.217002
IDR 18292.95
ILS 3.34105
IMP 0.764421
INR 92.680501
IQD 1513.506127
IRR 1937364.503067
ISK 125.10978
JEP 0.764421
JMD 158.14695
JOD 0.709027
JPY 158.55497
KES 129.831914
KGS 87.450227
KHR 4073.247392
KMF 449.000228
KPW 900.00035
KRW 1345.904997
KWD 0.31178
KYD 0.831959
KZT 455.400173
LAK 22505.352344
LBP 89404.637179
LKR 332.009293
LRD 167.220881
LSL 17.451373
LTL 2.95274
LVL 0.60489
LYD 6.459254
MAD 9.983601
MDL 18.299094
MGA 4524.210814
MKD 56.078896
MMK 2100.280273
MNT 3608.279079
MOP 8.060128
MRU 40.693299
MUR 46.779818
MVR 15.41069
MWK 1731.152918
MXN 19.11445
MYR 4.112971
MZN 63.897601
NAD 17.451373
NGN 1355.000009
NIO 36.742131
NOK 9.763685
NPR 147.947889
NZD 1.823764
OMR 0.381679
PAB 0.998315
PEN 3.426958
PGK 4.494147
PHP 64.017999
PKR 275.965381
PLN 4.06337
PYG 6295.267162
QAR 3.649342
RON 4.8778
RSD 107.165308
RUB 81.477338
RWF 1474.878149
SAR 3.751806
SBD 8.124013
SCR 13.993985
SDG 601.497036
SEK 10.155275
SGD 1.289399
SHP 0.764263
SLE 22.850218
SLL 20969.503664
SOS 570.582608
SRD 37.363503
STD 20697.981008
STN 22.320412
SVC 8.735025
SYP 13002.000337
SZL 17.447274
THB 34.044941
TJS 9.179702
TMT 3.5
TND 3.023915
TOP 2.40776
TRY 50.538796
TTD 6.776295
TWD 32.969599
TZS 2663.052886
UAH 44.835512
UGX 4218.102309
UYU 40.595818
UZS 11951.897235
VES 917.61775
VND 25801.5
VUV 120.826687
WST 2.823281
XAF 597.806237
XAG 0.024398
XAU 0.00028370404
XCD 2.70255
XCG 1.799299
XDR 0.707052
XOF 597.806237
XPF 108.650298
YER 236.602396
ZAR 17.50875
ZMK 9001.200242
ZMW 20.555733
ZWL 321.999592
SSP 5775.741752
MXV 2.142669
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

In abortion pill case, US high court may undermine drug regulator
In abortion pill case, US high court may undermine drug regulator / Photo: © AFP/File

In abortion pill case, US high court may undermine drug regulator

If the US Supreme Court, which on Tuesday hears a sensitive case on the availability of abortion pills, ultimately decides to restrict their access, it will impinge on the scientific authority of the federal Food and Drug Administration in unprecedented and consequential ways.

Text size:

While the case specifically deals with access to mifepristone -- the first of two pills taken in medication abortions -- a broad ruling could threaten access to a number of other drugs used for a wide variety of conditions, experts tell AFP.

The mifepristone pill, first authorized by the FDA in 2000, is now used in nearly two-thirds of all abortions in the United States. It has been deemed safe and legal in dozens of other countries.

In 2016, the FDA eased some restrictions on the drug's distribution, allowing it to be prescribed through the first 10 weeks of pregnancy (up from seven); permitting health professionals including nurses, and not just doctors, to prescribe it; and requiring only one consultation, down from the previous three.

Then, when the Covid-19 pandemic struck, the FDA allowed the pills to be sent by mail, following a single online medical visit.

But after a group of anti-abortion doctors and organizations brought suit, claiming the drug is unsafe and the approval process flawed, an appeals court last year ordered the FDA to return to its pre-2016 standards.

The Supreme Court will take up the case on Tuesday.

"For a judge to second-guess FDA's expert determination is inappropriate, it is unprecedented, and it's also extremely dangerous," Liz Borkowski, a public and women's health expert at George Washington University, told AFP.

"We could see frivolous litigation against all kinds of drugs that people have been using safely for years" -- potentially involving contraception, vaccines or hormonal therapy -- simply because some organization opposes them, she said.

- Black robes v. white lab coats -

From its creation, the FDA, whose decisions are often followed by other countries, has been charged with determining the effectiveness and safety of new medications. It regularly calls on independent experts as part of a carefully regulated review process.

Courts have questioned certain FDA decisions, notably over the interpretation of patents, said Lewis Grossman, a lawyer who has filed a brief in the case with the Supreme Court.

But "imposing restrictions on the availability of a drug based on a disagreement with the scientific experts at FDA," he told AFP, would be "very unprecedented."

"Interpreting science," he added, "is not a legal task."

The anti-abortion plaintiffs argue that when the FDA was reviewing its rules in 2016, it should have studied the impact of all the changes taken together -- an approach that Grossman called "just a made-up requirement by the plaintiffs."

Added Borkowski: "We have decades of evidence about the safety and efficacy of mifepristone.

"If mifepristone cannot stay on the market, as it is, with all these mountains of evidence that we have, then no drug is safe."

- Drugmakers worried -

The pharmaceutical industry strongly opposes a judicial intervention in the matter.

If the appeals court decision is confirmed, it would "inject an intolerable level of uncertainty into the drug approval process," according to a brief filed jointly by dozens of pharmaceutical companies and executives.

And that, the brief argues, would have the effect of "undercutting drug development and investment, and chilling innovation."

Experts said the court's ruling could even open the door for drugmakers to sue the FDA to block rivals from marketing competing medications.

The high court's involvement in rule setting could also place a huge array of agency decisions -- regarding scientific assessments of the environment, workplace safety or many other issues -- at risk of being overturned, according to Grossman.

Borkowski believes the court should take a firm position in the opposite direction, stating clearly that "it's never okay for judges to insert themselves in the science."

She admitted, however, that she worries about the outcome, given some of the conservative court's recent decisions.

Notably, the court in 2022 overturned the long-standing federal protection for abortion rights, leaving it up to each of the country's 50 states to pass its own laws on the matter.

Since then, some 15 Republican-led states have banned abortion -- including through the use of abortion pills. For now, though, women in those states can still receive them -- by mail.

A ruling is expected by summer.

A.Williams--TFWP